Meridian Bioscience (VIVO) Misses Q4 EPS by 1c

Meridian Bioscience (NASDAQ: VIVO) reported Q4 EPS of $0.20, $0.01 worse than the analyst estimate of $0.21. Revenue for the quarter came in at $47.1 million versus the consensus estimate of $46.6 million.

For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.

You May Also Be Interested In

• Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
• JPMorgan Reinstates Dauch Corporation (DCH) at Neutral
• Goldman Sachs Downgrades Daihen Corp (6622:JP) to Neutral